Top Markets
Coin of the day
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Classifica tra le azioni #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Prezzo delle azioni
$2.72
Ultima sincronizzazione: 2023-10-19
Capitalizzazione di mercato
$111.47M
Variazione (1 giorno)
-0.73%
Variazione (1 anno)
0.00%
Paese
US
Scambia Talaris Therapeutics, Inc. (TALS)

Categoria

Rapporto P/S per Talaris Therapeutics, Inc. (TALS)
Rapporto P/S al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Talaris Therapeutics, Inc., il rapporto P/S attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/S per Talaris Therapeutics, Inc. da 2026 a 2026
Rapporto P/S alla fine di ogni anno
Anno Rapporto P/S Cambia
Non abbastanza dati per le date fornite.
Rapporto P/S per aziende simili o concorrenti
Azienda Rapporto P/S Differenza del rapporto P/S Il paese
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH